You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
永泰生物-B(06978.HK)6B11-OCIK注射液完成中國一期臨床試驗的首例患者入組
阿思達克 01-31 09:29
永泰生物-B(06978.HK)公布,集團其中一款在研產品6B11-OCIK注射液已於星期六(29日)完成中國一期臨床試驗的首例患者入組。該注射液利用6B11可在體外誘導出特異的抗卵巢癌體液免疫和細胞免疫抗體,經過體外培養增殖後(6B11-OCIK注射液)回輸給受試者以達到特異殺傷腫瘤細胞的目的。 集團表示,根據6B11-OCIK注射液的臨床試驗進展,如無意外情況發生,預計目標患者招募最早將於2022年第三季完成,並將於2022年公布初步分析及結果。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account